The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
Jean Jacques Bienaime, insider at BioMarin Pharmaceutical

Jean Jacques Bienaime Insider Information

Jean Jacques Bienaime is the chairman and CEO at BioMarin, a world leader in developing and commercializing first- or best-in-class therapies for rare genetic diseases.

Bienaimé joined BioMarin in 2005 as CEO and a member of the board of directors, bringing more than 25 years of biotechnology and pharmaceutical experience. He is credited with the company’s significant growth in revenue, employees, and stature. Under his direction, BioMarin’s market capitalization went from approximately $450 million to around $14 billion. 

Prior to BioMarin, Bienaimé was the chairman, CEO, and president of Genencor, a leading biotechnology company and a pioneer in enzyme innovation.

During his tenure, the company’s revenues experienced a significant increase to more than $400 million, and in 2005, it was sold to Danisco at an enterprise value of more than $1.2 billion.

Before Genencor, Bienaimé was the chairman, CEO, and president of Sangstat Medical Corporation, where he managed revenue growth, bringing it to profitability before it was acquired by Genzyme Corporation.

Previously, he held senior management roles at Rhone-Poulenc Rorer Pharmaceuticals (now SanofiAventis), including senior vice president of worldwide marketing and business development. In this role, he was responsible for the U.S. launch of Lovenox® and the global launch of Taxotere®. He also worked for Genentech, Inc. where he was involved with the launch of tissue plasminogen activator (t-PA).

Bienaimé currently sits on the board of Incyte Corporation, as well as those of industry trade organizations, PhRMA and Biotechnology Innovation Organization (BIO). He has previously served on the boards of Portola Pharmaceuticals, Inc., InterMune, Inc., and Vital Therapies, Inc., among others. 

In 2020, he was recognized as one of The Healthcare Technology Report’s “Top 50 Healthcare Technology CEOs.”

Bienaimé earned a degree in economics at the École Supérieure de Commerce de Paris and an M.B.A. from the Wharton School at the University of Pennsylvania 

What is Jean Jacques Bienaime's net worth?

The estimated net worth of Jean Jacques Bienaime is at least $32.19 million as of May 5th, 2022. Mr. Bienaime owns 335,324 shares of BioMarin Pharmaceutical stock worth more than $32,191,104 as of August 10th. This net worth evaluation does not reflect any other investments that Mr. Bienaime may own. Additionally, Mr. Bienaime receives a salary of $3,670,000.00 as CEO at BioMarin Pharmaceutical. Learn More about Jean Jacques Bienaime's net worth.

How old is Jean Jacques Bienaime?

Mr. Bienaime is currently 69 years old. There are 5 older executives and no younger executives at BioMarin Pharmaceutical. Learn More on Jean Jacques Bienaime's age.

What is Jean Jacques Bienaime's salary?

As the CEO of BioMarin Pharmaceutical Inc., Mr. Bienaime earns $3,670,000.00 per year. Learn More on Jean Jacques Bienaime's salary.

How do I contact Jean Jacques Bienaime?

The corporate mailing address for Mr. Bienaime and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected] Learn More on Jean Jacques Bienaime's contact information.

Has Jean Jacques Bienaime been buying or selling shares of BioMarin Pharmaceutical?

Jean Jacques Bienaime has not been actively trading shares of BioMarin Pharmaceutical during the last ninety days. Most recently, Jean Jacques Bienaime sold 10,000 shares of the business's stock in a transaction on Thursday, May 5th. The shares were sold at an average price of $84.14, for a transaction totalling $841,400.00. Following the completion of the sale, the chief executive officer now directly owns 335,324 shares of the company's stock, valued at $28,214,161.36. Learn More on Jean Jacques Bienaime's trading history.

Who are BioMarin Pharmaceutical's active insiders?

BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Jean Bienaime (CEO), George Davis (EVP), Willard Dere (Director), Henry Fuchs (Insider), Michael Grey (Director), V. Lawlis (Director), Richard Meier (Director), Brian Mueller (CFO), David Pyott (Director), and Dennis Slamon (Director). Learn More on BioMarin Pharmaceutical's active insiders.

Are insiders buying or selling shares of BioMarin Pharmaceutical?

In the last twelve months, insiders at the biotechnology company sold shares 22 times. They sold a total of 167,259 shares worth more than $13,852,486.85. The most recent insider tranaction occured on July, 8th when EVP George Eric Davis sold 7,398 shares worth more than $665,820.00. Insiders at BioMarin Pharmaceutical own 1.8 % of the company. Learn More about insider trades at BioMarin Pharmaceutical.

Information on this page was last updated on 7/8/2022.

Jean Jacques Bienaime Insider Trading History at BioMarin Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/5/2022Sell10,000$84.14$841,400.00335,324View SEC Filing Icon  
4/28/2022Sell20,000$83.79$1,675,800.00334,983View SEC Filing Icon  
4/18/2022Sell20,000$81.91$1,638,200.00334,983View SEC Filing Icon  
4/14/2022Sell10,000$83.66$836,600.00334,983View SEC Filing Icon  
3/10/2022Sell15,000$77.57$1,163,550.00View SEC Filing Icon  
1/13/2022Sell5,000$87.86$439,300.00View SEC Filing Icon  
12/15/2021Sell6,000$82.71$496,260.00View SEC Filing Icon  
12/1/2021Sell1,500$87.22$130,830.00View SEC Filing Icon  
5/10/2021Sell8,513$77.29$657,969.77312,352View SEC Filing Icon  
5/7/2021Sell25,000$78.12$1,953,000.00303,839View SEC Filing Icon  
4/23/2021Sell10,000$79.34$793,400.00312,498View SEC Filing Icon  
3/11/2021Sell7,000$77.68$543,760.00295,652View SEC Filing Icon  
2/19/2021Sell7,000$83.58$585,060.00302,552View SEC Filing Icon  
2/17/2021Sell8,000$84.54$676,320.00303,552View SEC Filing Icon  
1/29/2021Sell8,334$82.67$688,971.78303,885View SEC Filing Icon  
1/27/2021Sell8,333$85.49$712,388.17303,885View SEC Filing Icon  
12/28/2020Sell1,500$88.77$133,155.00297,052View SEC Filing Icon  
5/8/2020Sell20,000$91.72$1,834,400.00318,552View SEC Filing Icon  
5/4/2020Sell5,000$88.00$440,000.00298,552View SEC Filing Icon  
5/1/2020Sell4,000$89.38$357,520.00298,552View SEC Filing Icon  
4/28/2020Sell20,000$97.58$1,951,600.00318,213View SEC Filing Icon  
4/9/2020Sell10,000$79.06$790,600.00308,213View SEC Filing Icon  
3/9/2020Sell10,000$89.52$895,200.00296,443View SEC Filing Icon  
1/14/2020Sell8,000$87.95$703,600.00335,530View SEC Filing Icon  
1/7/2020Sell3,000$84.46$253,380.00330,530View SEC Filing Icon  
12/27/2019Sell5,000$86.16$430,800.00View SEC Filing Icon  
11/22/2019Sell10,000$77.60$776,000.00327,070View SEC Filing Icon  
10/25/2019Sell5,000$69.55$347,750.00332,520View SEC Filing Icon  
5/10/2019Sell10,000$82.52$825,200.00336,520View SEC Filing Icon  
5/8/2019Sell4,000$82.16$328,640.00326,520View SEC Filing Icon  
4/26/2019Sell3,000$82.88$248,640.00329,211View SEC Filing Icon  
4/12/2019Sell4,000$89.12$356,480.00325,211View SEC Filing Icon  
4/8/2019Sell3,000$91.87$275,610.00327,211View SEC Filing Icon  
4/5/2019Sell3,000$93.37$280,110.00327,211View SEC Filing Icon  
3/25/2019Sell4,000$87.86$351,440.00323,211View SEC Filing Icon  
3/15/2019Sell4,000$94.40$377,600.00300,558View SEC Filing Icon  
3/12/2019Sell9,000$90.06$810,540.00333,701View SEC Filing Icon  
3/7/2019Sell4,000$90.78$363,120.00332,701View SEC Filing Icon  
2/27/2019Sell4,000$91.78$367,120.00292,290View SEC Filing Icon  
2/21/2019Sell3,000$90.12$270,360.00291,290View SEC Filing Icon  
2/14/2019Sell4,000$95.20$380,800.00292,290View SEC Filing Icon  
2/5/2019Sell4,000$98.63$394,520.00292,290View SEC Filing Icon  
1/22/2019Sell3,000$96.82$290,460.00291,290View SEC Filing Icon  
1/14/2019Sell4,000$93.79$375,160.00292,290View SEC Filing Icon  
1/10/2019Sell3,000$90.55$271,650.00291,290View SEC Filing Icon  
1/7/2019Sell3,000$87.58$262,740.00291,290View SEC Filing Icon  
12/28/2018Sell3,000$84.04$252,120.00View SEC Filing Icon  
12/28/2018Sell3,000$84.04$252,120.00291,290View SEC Filing Icon  
12/26/2018Sell4,000$80.50$322,000.00292,290View SEC Filing Icon  
12/14/2018Sell2,000$92.64$185,280.00290,290View SEC Filing Icon  
12/12/2018Sell2,000$93.12$186,240.00290,290View SEC Filing Icon  
11/1/2018Sell4,000$92.55$370,200.00292,290View SEC Filing Icon  
10/3/2018Sell1,500$99.36$149,040.00287,790View SEC Filing Icon  
9/4/2018Sell1,500$98.16$147,240.00286,790View SEC Filing Icon  
7/23/2018Sell1,500$101.69$152,535.00286,790View SEC Filing Icon  
5/17/2018Sell18,750$88.66$1,662,375.00309,350View SEC Filing Icon  
5/15/2018Sell37,500$88.75$3,328,125.00309,350View SEC Filing Icon  
5/11/2018Sell18,750$88.42$1,657,875.00View SEC Filing Icon  
4/24/2018Sell20,000$82.43$1,648,600.00300,031View SEC Filing Icon  
4/20/2018Sell10,000$83.65$836,500.00300,031View SEC Filing Icon  
3/15/2018Sell15,000$84.73$1,270,950.00279,674View SEC Filing Icon  
2/15/2018Sell10,000$84.63$846,300.00View SEC Filing Icon  
1/5/2018Sell10,000$90.32$903,200.00235,894View SEC Filing Icon  
12/29/2017Sell20,000$89.75$1,795,000.00View SEC Filing Icon  
12/29/2017Sell10,000$89.61$896,100.00226,494View SEC Filing Icon  
6/5/2017Sell10,000$90.13$901,300.00238,564View SEC Filing Icon  
5/24/2017Sell5,000$88.38$441,900.00238,564View SEC Filing Icon  
5/17/2017Sell5,000$91.73$458,650.00238,564View SEC Filing Icon  
5/8/2017Sell10,000$96.09$960,900.00238,496View SEC Filing Icon  
4/27/2017Sell5,000$95.72$478,600.00243,194View SEC Filing Icon  
4/25/2017Sell5,000$94.00$470,000.00243,194View SEC Filing Icon  
3/16/2017Sell10,000$91.69$916,900.00211,364View SEC Filing Icon  
3/10/2017Sell11,000$90.59$996,490.00212,364View SEC Filing Icon  
1/26/2017Sell10,000$84.22$842,200.00175,682View SEC Filing Icon  
1/11/2017Sell8,000$90.58$724,640.00174,682View SEC Filing Icon  
1/9/2017Sell8,000$88.49$707,920.00174,682View SEC Filing Icon  
12/30/2016Sell8,000$83.60$668,800.00174,682View SEC Filing Icon  
11/22/2016Sell69,743$85.69$5,976,277.67View SEC Filing Icon  
11/21/2016Sell69,744$87.56$6,106,784.64View SEC Filing Icon  
11/8/2016Sell140,000$82.67$11,573,800.00393,368View SEC Filing Icon  
11/7/2016Sell70,000$82.52$5,776,400.00393,368View SEC Filing Icon  
10/28/2016Sell120,000$81.30$9,756,000.00383,368View SEC Filing Icon  
10/17/2016Sell41,666$84.39$3,516,193.74365,034View SEC Filing Icon  
10/14/2016Sell64,125$86.96$5,576,310.00378,184View SEC Filing Icon  
9/29/2016Sell53,125$93.65$4,975,156.25431,709View SEC Filing Icon  
9/16/2016Sell137,368$95.34$13,096,665.12421,161View SEC Filing Icon  
8/16/2016Sell41,666$91.49$3,812,022.34420,250View SEC Filing Icon  
7/18/2016Sell41,666$92.72$3,863,271.52420,250View SEC Filing Icon  
6/16/2016Sell41,666$80.55$3,356,196.30420,250View SEC Filing Icon  
5/5/2016Sell50,000$80.15$4,007,500.00390,156View SEC Filing Icon  
5/2/2016Sell36,500$85.01$3,102,865.00395,635View SEC Filing Icon  
3/1/2016Sell10,000$84.28$842,800.00350,500View SEC Filing Icon  
11/30/2015Sell1,000$94.74$94,740.00228,754View SEC Filing Icon  
10/15/2015Sell1,000$108.24$108,240.00228,754View SEC Filing Icon  
9/14/2015Sell1,000$131.43$131,430.00228,754View SEC Filing Icon  
7/7/2015Sell1,500$139.07$208,605.00View SEC Filing Icon  
3/17/2015Sell2,000$124.17$248,340.00View SEC Filing Icon  
3/16/2015Sell1,000$123.48$123,480.00View SEC Filing Icon  
3/10/2015Sell21,021$112.39$2,362,550.19View SEC Filing Icon  
3/9/2015Sell19,000$112.13$2,130,470.00View SEC Filing Icon  
3/5/2015Sell10,000$113.70$1,137,000.00View SEC Filing Icon  
3/4/2015Sell13,916$107.92$1,501,814.72View SEC Filing Icon  
3/3/2015Sell5,000$107.42$537,100.00View SEC Filing Icon  
3/2/2015Sell5,000$108.44$542,200.00View SEC Filing Icon  
1/9/2015Sell2,000$94.14$188,280.00View SEC Filing Icon  
12/24/2014Sell5,000$88.73$443,650.00View SEC Filing Icon  
12/10/2014Sell2,000$95.00$190,000.00View SEC Filing Icon  
11/25/2014Sell2,000$90.00$180,000.00View SEC Filing Icon  
11/12/2014Sell1,000$81.51$81,510.00View SEC Filing Icon  
11/10/2014Sell4,000$87.00$348,000.00View SEC Filing Icon  
11/3/2014Sell3,000$85.33$255,990.00View SEC Filing Icon  
10/24/2014Sell2,000$80.00$160,000.00View SEC Filing Icon  
8/20/2014Sell5,000$70.00$350,000.00View SEC Filing Icon  
6/4/2014Sell2,000$61.20$122,400.00View SEC Filing Icon  
5/22/2014Sell1,000$56.88$56,880.00180,257View SEC Filing Icon  
5/21/2014Sell1,545$56.19$86,813.55180,257View SEC Filing Icon  
12/24/2013Sell10,000$68.71$687,100.00View SEC Filing Icon  
12/5/2013Sell5,000$69.70$348,500.00View SEC Filing Icon  
10/16/2013Sell2,000$67.73$135,460.00View SEC Filing Icon  
10/10/2013Sell3,000$66.76$200,280.00View SEC Filing Icon  
9/16/2013Sell2,000$73.08$146,160.00View SEC Filing Icon  
8/15/2013Sell1,000$64.36$64,360.00View SEC Filing Icon  
5/21/2013Sell2,000$64.14$128,280.00View SEC Filing Icon  
5/16/2013Sell12,000$67.90$814,800.00View SEC Filing Icon  
5/14/2013Sell15,000$70.17$1,052,550.00View SEC Filing Icon  
5/13/2013Sell15,800$68.77$1,086,566.00View SEC Filing Icon  
5/8/2013Sell4,000$65.87$263,480.00View SEC Filing Icon  
5/2/2013Sell3,000$64.99$194,970.00View SEC Filing Icon  
2/4/2013Sell2,000$55.77$111,540.00View SEC Filing Icon  
12/27/2012Sell17,000$48.37$822,290.00View SEC Filing Icon  
See Full Table

Jean Jacques Bienaime Buying and Selling Activity at BioMarin Pharmaceutical

This chart shows Jean Jacques Bienaime's buying and selling at BioMarin Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioMarin Pharmaceutical Company Overview

BioMarin Pharmaceutical logo
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $96.00
Low: $94.41
High: $96.38

50 Day Range

MA: $83.51
Low: $71.48
High: $95.82

2 Week Range

Now: $96.00
Low: $70.73
High: $97.76

Volume

1,206,676 shs

Average Volume

1,245,127 shs

Market Capitalization

$17.81 billion

P/E Ratio

369.24

Dividend Yield

N/A

Beta

0.33
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!